What is the drug of choice for uncomplicated typhoid fever in an otherwise healthy adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Drug of Choice for Typhoid Fever

For uncomplicated typhoid fever in otherwise healthy adults, azithromycin is the preferred first-line agent, with ceftriaxone as the alternative, particularly in areas with quinolone resistance. 1

Treatment Algorithm Based on Resistance Patterns

First-Line Therapy

Azithromycin demonstrates superior outcomes compared to both fluoroquinolones and ceftriaxone:

  • Lower clinical failure rates (OR 0.48) compared to fluoroquinolones
  • Shorter hospital stays by approximately 1 day
  • Dramatically lower relapse rates (OR 0.09) compared to ceftriaxone 1

Alternative First-Line Options

For fully susceptible strains (increasingly rare):

  • Fluoroquinolones (ciprofloxacin, ofloxacin, gatifloxacin) remain effective 1
  • However, widespread quinolone resistance has emerged globally, particularly nalidixic acid resistance which predicts fluoroquinolone treatment failure 2

For quinolone-resistant strains (now common):

  • Azithromycin or ceftriaxone are recommended 1
  • Cefixime as oral alternative 1

Critical Resistance Considerations

The evidence reveals a crucial pitfall: nalidixic acid resistance strongly predicts fluoroquinolone failure. In one study, 3 of 5 patients (60%) with nalidixic acid-resistant strains failed fluoroquinolone therapy, compared to only 4% with sensitive strains (relative risk 13.5) 2. This makes susceptibility testing essential before choosing fluoroquinolones.

Additionally, a trial comparing gatifloxacin to ceftriaxone was stopped early due to emergence of high-level fluoroquinolone resistance, and ceftriaxone showed lower failure rates in culture-confirmed cases (HR 0.24) 1.

Practical Treatment Approach

Step 1: Assess Local Resistance Patterns

  • If quinolone resistance >5-10%: Start azithromycin
  • If multidrug-resistant (chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole): Avoid older agents entirely 1
  • If extensively drug-resistant (XDR): Azithromycin and/or meropenem required 3, 4

Step 2: Choose Initial Empiric Therapy

Preferred: Azithromycin (oral, well-tolerated, effective against resistant strains)

Alternative: Ceftriaxone (IV/IM, particularly if severely ill or azithromycin resistance suspected)

Step 3: Adjust Based on Culture Results

  • Obtain blood cultures before starting antibiotics
  • Perform antimicrobial susceptibility testing
  • Switch to narrower spectrum if fully susceptible organism identified

Important Caveats

Older antibiotics are obsolete for empiric therapy: Chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole show higher clinical failure rates than modern agents and should not be used empirically given widespread resistance 1.

WHO guidelines from 2003-2012 are outdated: These recommend fluoroquinolones first-line 1, but resistance patterns have fundamentally changed since publication. The 2024 evidence synthesis showing azithromycin superiority reflects current reality.

Geographic variation matters: The XDR outbreak in Pakistan since 2016 has created pockets where only azithromycin and carbapenems remain effective 4. Know your local epidemiology.

Treatment duration: While shorter fluoroquinolone courses (2-3 days) were studied 2, standard azithromycin courses are typically 5-7 days, and ceftriaxone 10-14 days. Don't abbreviate courses with resistant organisms.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.